Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Alteplase (Actilyse® Cathflo® 2 mg) is recommended as an option for use within NHS Wales for the thrombolytic treatment of occluded central venous access devices including those used for haemodialysis. AWMSG is of the opinion that alteplase (Actilyse® Cathflo® 2 mg) is not suitable for shared care within NHS Wales. |
|||
|
|||
Medicine details |
|||
| Medicine name | alteplase (Actilyse® Cathflo®) | ||
| Formulation | 2 mg powder and solvent for solution for injection / infusion | ||
| Reference number | 722 | ||
| Indication | Thrombolytic treatment of occluded central venous access devices including those used for haemodialysis |
||
| Company | Boehringer Ingelheim Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1911 | ||
| NMG meeting date | 03/11/2011 | ||
| AWMSG meeting date | 07/12/2011 | ||
| Ratification by Welsh Government | 09/01/2012 | ||
| Date of issue | 12/01/2012 | ||